Iscartrelvir
生产企业：Westlake Pharmaceuticals
Iscartrelvir (Mprosevir) is a small-molecule antiviral drug jointly developed by Westlake University, Westlake Laboratory and Westlake Pharmaceuticals, which received conditional marketing approval from China's NMPA for the treatment of mild to moderate COVID-19 infections in adults. It is China's first AI-assisted "Class 1" innovative drug and the world's first small-molecule innovative drug approved based on DNA-encoded library (DEL) technology.
Iscartrelvir (Mprosevir) is a small-molecule antiviral drug jointly developed by Westlake University, Westlake Laboratory and Westlake Pharmaceuticals, which received conditional marketing approval from China's NMPA for the treatment of mild to moderate COVID-19 infections in adults. It is China's first AI-assisted "Class 1" innovative drug and the world's first small-molecule innovative drug approved based on DNA-encoded library (DEL) technology.
用于治疗成人轻型、中型新型冠状病毒感染（COVID-19）。
共 1 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
